Shopping Cart
Remove All
Your shopping cart is currently empty
Osocimab
(Synonyms: BAY 1213790) Copy Product Info
🥰Excellent
Synonyms: BAY 1213790
Catalog No. T77124 Copy Product Info
🥰Excellent
Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition.Osocimab is often used as an XI factor inhibitor, has an inhibitory effect on thrombin generation, has an anticoagulant effect, and is used in the study of thromboembolic diseases. Thromboembolic Diseases
Cas No. 2056878-75-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $163 | In Stock | In Stock | |
| 5 mg | $496 | In Stock | In Stock | |
| 10 mg | $795 | - | In Stock | |
| 25 mg | $1,180 | - | In Stock | |
| 50 mg | $1,580 | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:> 95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition.Osocimab is often used as an XI factor inhibitor, has an inhibitory effect on thrombin generation, has an anticoagulant effect, and is used in the study of thromboembolic diseases. Thromboembolic Diseases |
| Targets & IC50 | FIX activation:16 nM, Substrate cleavage (FXIa mediated):1.2 nM |
| In vitro | In human plasma, Osocimab (1.4 nM-1 μM; 30 min) demonstrated inhibition of thrombin production, as well as FXIa-mediated FIX activation (or FIX conversion) with an IC50 of 16 nM and FXIa-mediated substrate cleavage with an IC50 of 1.2 nM [1]. Osocimab, at a concentration of 22.05 mg/mL, inhibited activation of the intrinsic pathway-mediated coagulation cascade [1]. |
| Endotoxin | <1.0 EU/mg |
| Synonyms | BAY 1213790 |
| Reactivity | Human |
| Verified Activity | Immobilized Human Coagulation factor XI/F11 Protein (His) (TMPY-01104) at 1 μg/mL (100 μL/well) can bind Osocimab. The EC50 is 2.81 ng/mL. |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | F11/Factor XI |
| Molecular Weight | 144.46 kDa |
| Cas No. | 2056878-75-0 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Keywords
Preview
Related Tags: Osocimab chemical structure | Osocimab in vitro | Osocimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.